About pSivida Corp.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drugs - Generic
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: PSDV
- Previous Close: $1.75
- 50 Day Moving Average: $1.81
- 200 Day Moving Average: $2.43
- 52-Week Range: $1.50 - $4.25
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -8.09
- P/E Growth: 0.00
- Market Cap: $60.83M
- Outstanding Shares: 34,176,000
- Beta: 1.74
- Net Margins: -271.33%
- Return on Equity: -97.39%
- Return on Assets: -66.37%
Companies Related to pSivida Corp.:
- Current Ratio: 3.77%
- Quick Ratio: 3.77%
What is pSivida Corp.'s stock symbol?
pSivida Corp. trades on the NASDAQ under the ticker symbol "PSDV."
Where is pSivida Corp.'s stock going? Where will pSivida Corp.'s stock price be in 2017?
1 analysts have issued 12-month price targets for pSivida Corp.'s stock. Their forecasts range from $7.00 to $7.00. On average, they expect pSivida Corp.'s stock price to reach $7.00 in the next year.
When will pSivida Corp. announce their earnings?
pSivida Corp. is scheduled to release their next quarterly earnings announcement on Wednesday, May, 3rd 2017.
Who owns pSivida Corp. stock?
pSivida Corp.'s stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (6.67%), Deerfield Management Co. (4.37%), Renaissance Technologies LLC (2.65%), North Run Capital LP (2.63%) and Bard Associates Inc. (0.30%). Company insiders that own pSivida Corp. stock include Leonard S Ross and Paul Ashton.
Who sold pSivida Corp. stock? Who is selling pSivida Corp. stock?
pSivida Corp.'s stock was sold by a variety of institutional investors in the last quarter, including North Run Capital LP and Bard Associates Inc..
Who bought pSivida Corp. stock? Who is buying pSivida Corp. stock?
pSivida Corp.'s stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC and Renaissance Technologies LLC.
How do I buy pSivida Corp. stock?
Shares of pSivida Corp. can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of pSivida Corp. stock cost?
One share of pSivida Corp. stock can currently be purchased for approximately $1.78.